161 related articles for article (PubMed ID: 32279331)
1. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract][Full Text] [Related]
2. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
[TBL] [Abstract][Full Text] [Related]
3. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
5. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
[TBL] [Abstract][Full Text] [Related]
8. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.
Chase A; Bryant C; Score J; Haferlach C; Grossmann V; Schwaab J; Hofmann WK; Reiter A; Cross NC
Haematologica; 2013 Mar; 98(3):404-8. PubMed ID: 22875628
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
[No Abstract] [Full Text] [Related]
12. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
[TBL] [Abstract][Full Text] [Related]
13. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
14. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
Xie W; Wang SA; Hu S; Xu J; Medeiros LJ; Tang G
Cancer Genet; 2018 Dec; 228-229():41-46. PubMed ID: 30553471
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C; Cross NC; Van Etten RA; Reiter A
Leukemia; 2008 Jul; 22(7):1320-34. PubMed ID: 18528425
[TBL] [Abstract][Full Text] [Related]
17. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
18. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
19. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
[TBL] [Abstract][Full Text] [Related]
20. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
